EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir.

Trial Profile

EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2012

At a glance

  • Drugs Bortezomib (Primary) ; Ganciclovir
  • Indications Burkitt's lymphoma; Epstein-Barr virus infections; Hodgkin's disease; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2010 Planned end date (Jul 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top